A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab
Open Access
- 29 November 2022
- journal article
- letter
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (3) , 1146-1148
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b TrialAdvances in Therapy, 2021
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialThe Lancet, 2021
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialThe Lancet, 2021
- A case of erythrodermic psoriasis successfully treated with guselkumabDermatologic Therapy, 2020
- Systematic review on rapidity of onset of action for interleukin‐17 and interleukin‐23 inhibitors for psoriasisJournal of the European Academy of Dermatology and Venereology, 2019
- IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in PsoriasisJournal of Investigative Dermatology, 2017
- Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic DermatitisJAMA Dermatology, 2015